HSR&D Citation Abstracts
Search | Search by Center | Search by Source | Keywords in Title
Jia X, Kohli P, Virani SS. Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. Current Atherosclerosis Reports. 2019 Jan 10; 21(1):1.
PURPOSE OF REVIEW:
Omega-3 fatty acids ( -3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings.
Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of -3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Given the different formulations, dosages, and patient populations studied, CVOTs of -3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid -3 FA formulations provide additional benefit in reduction of ASCVD events.